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We recently published an analysis of an infant
pneumococcal vaccine policy shift that consid-
ered the potential clinical impact and cost-
effectiveness of a switch from the 13-valent
(PCV13) to the 10-valent pneumococcal conju-
gate vaccine (PCV10) in Canada [1]. Our study
estimated the incremental disease predicted to
occur in Canada should there be a change in
vaccination program from PCV13 to PCV10,
using historical trends of individual serotypes
contained in these vaccines. The model esti-
mated that the switch could result in an addi-
tional 726,531 cases of disease over 10 years and
that, despite a higher vaccine acquisition cost of
PCV13, the net savings from lower disease
incidence with continued PCV13 use would be
[$500 million.
A limitation of this predictive modeling was
that scarce real-world evidence of such a switch
from a higher to lower valent vaccine existed.
Thus, a number of assumptions were included
in the analysis to mitigate potential over- or
underestimation of serotype dynamics. A criti-
cal assumption was that no changes in the ser-
otypes that are unique to PCV13 (3, 6A, 19A)
would be observed for at least 2 years after a
vaccine policy change given the residual influ-
ence of many cohorts previously vaccinated
with PCV13.
Since the publication of our model, surveil-
lance data from Belgium have been published
highlighting the real-world impact of a change
from PCV13 to PCV10 [2]. Belgium introduced
the 7-valent PCV (PCV7) in 2007 and subse-
quently replaced PCV7 with PCV13 in 2011.
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After near elimination of serotype 19A invasive
pneumococcal disease (IPD) in Belgian chil-
dren B 2 years of age (2 cases each were repor-
ted in 2015 and 2016), a switch to PCV10 was
made in the two regional immunization pro-
grams in July 2015 (Flanders) and May 2016
(Wallonia). By the end of 2017, only 8–
18 months following the switch, a nationwide
ten-fold increase in serotype 19A IPD cases in
children B 2 years of age was observed (21 cases
reported). This increase continued in 2018, with
ten serotype 19A isolates detected in the first
quarter of the year [2].
Acknowledging the complexities in inter-
preting these data and inherent difficulties in
assessing causalities, these data could support
our analysis and may suggest that our original
assumptions and results could be conservative.
In our model, assuming that re-emergence of
previously covered serotypes could begin in
children after only 1 year following the switch
to PCV10 would result in an additional 134,122
cases of pneumococcal disease over 10 years
compared with the original analysis (Table 1).
This would translate to an additional $57 mil-
lion in costs to the Canadian health system
because of fewer cases of disease.
While the reemergence of serotype 19A in
Belgium was rapid and statistically significant,
longer follow-up is necessary to determine
whether these trends continue and to better
understand potential causal relation with the
switch to PCV10. Analyzing changes in IPD in
non-vaccinated age groups (those not directly
influenced by the switch) is crucial to under-
standing the impact of both vaccines on herd
effect. This in turn can inform re-analyses of
predictive models that will determine the true
cost and effectiveness of changing PCV program
policies.
Taking the complexities of pneumococcal
epidemiology as well as the diverse direct and
indirect effects of vaccination into account, we
acknowledge limitations in our transfer of Bel-
gium findings to a completely different setting.
As was noted in a recently published corre-
spondence [2], there are limitations to these
data given the small sample size in passive
surveillance and short time horizon [3]. Few
examples of countries that have switched from
PCV13 to PCV10 exist; however, the only evi-
dence of impact beyond Belgium is from Casa-
blanca, Morocco, where in a single hospital
4 years after sequential PCV13 then PCV10
implementation no change in serotype 19A
across all years with PCV13 and PCV10 was
observed [4]. Ergo, our results should be con-
sidered with caution and be conceived as only
indicative of potential developments in the
years to come.
Table 1 Additional cases of pneumococcal disease in Canada with PCV10 vs. PCV13 over 10 years across all ages
2-Year laga 1-Year lag Difference
Number of cases of:
Pneumococcal bacteremia 3009 3146 137
Pneumococcal meningitis 1609 1682 73
Pneumococcal acute otitis media 709,073 839,881 130,808
Nonhospitalized pneumococcal pneumonia 10,285 12,790 2505
Hospitalized pneumococcal pneumonia 38,556 39,154 598
Total cases 762,531 896,653 134,122
Deaths 4399 4404 5
Total costs $523,307,951 $580,401,137 $57,093,186
a Results from Wilson et al. [1]
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